MONTREAL, March 20 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma today announced that Mr. Louis Guindon has resigned as Chief Financial Officer of the company effective March 19, 2008. Mr. Guindon intends to keep assisting the company on a consultancy basis. Biophage is presently considering different options for his replacement on an interim basis.
"The Board of Directors and Management wish to thank Mr. Guindon for his excellent approach in rationalizing expenses and strengthening the quality of the company's accounting practice over the past year. The scientific and technical staff joins the Board of Directors in wishing him the best of luck in his future career." concluded Dr Mandeville.
About Biophage Pharma Inc.
Biophage is a Canadian biotechnology company focused on the development of innovative phage-based products and technologies for the detection, prevention and control of bacterial infections. Biophage also operates the Immunotox Labs division, which provides services in Immunogenicity and Immunotoxicity, screening for Beryllium sensitization (the BeLPT test) and exclusive MELISA(R) for the detection of sensitization to more than 200 different allergens including metals, penicillin, gluten, pollens and more recently Lyme disease (Boreliosis).
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information
Rosemonde Mandeville, M.B., Ch.B., PhD., President and CEO, Biophage Pharma Inc., (514) 496-1488, firstname.lastname@example.org
Source: BIOPHAGE PHARMA, INC.